Global Cell and Gene Therapy CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cell and Gene Therapy CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Global Cell and Gene Therapy CDMO market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Pharmaceutical Company and Biotechnology Company are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cell and Gene Therapy CDMO industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Cell and Gene Therapy CDMO key companies include Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, BioCentriq, RoslinCT, Thermo Scientific and Mesoblast, etc. Lonza, Charles River Laboratories, Cytiva are top 3 players and held % share in total in 2022.
Cell and Gene Therapy CDMO can be divided into Clinical Trial Material CDMOs, Development and Manufacturing CDMOs and Other,, etc. Clinical Trial Material CDMOs is the mainstream product in the market, accounting for % share globally in 2022.
Cell and Gene Therapy CDMO is widely used in various fields, such as Pharmaceutical Company, Biotechnology Company and Other,, etc. Pharmaceutical Company provides greatest supports to the Cell and Gene Therapy CDMO industry development. In 2022, global % share of Cell and Gene Therapy CDMO went into Pharmaceutical Company filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cell and Gene Therapy CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
BioCentriq
RoslinCT
Thermo Scientific
Mesoblast
Cellularity
Bluebird Bio
Editas Medicine
Andelyn Biosciences
Wuxi Advanced Therapies
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
Segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cell and Gene Therapy CDMO market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cell and Gene Therapy CDMO introduction, etc. Cell and Gene Therapy CDMO Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cell and Gene Therapy CDMO market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
North America, Europe and Asia Pacific are the key regions for Cell and Gene Therapy CDMO industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Cell and Gene Therapy CDMO key companies include Lonza, Charles River Laboratories, Cytiva, Catalent Biologics, FUJIFILM Diosynth Biotechnologies, BioCentriq, RoslinCT, Thermo Scientific and Mesoblast, etc. Lonza, Charles River Laboratories, Cytiva are top 3 players and held % share in total in 2022.
Cell and Gene Therapy CDMO can be divided into Clinical Trial Material CDMOs, Development and Manufacturing CDMOs and Other,, etc. Clinical Trial Material CDMOs is the mainstream product in the market, accounting for % share globally in 2022.
Cell and Gene Therapy CDMO is widely used in various fields, such as Pharmaceutical Company, Biotechnology Company and Other,, etc. Pharmaceutical Company provides greatest supports to the Cell and Gene Therapy CDMO industry development. In 2022, global % share of Cell and Gene Therapy CDMO went into Pharmaceutical Company filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cell and Gene Therapy CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
BioCentriq
RoslinCT
Thermo Scientific
Mesoblast
Cellularity
Bluebird Bio
Editas Medicine
Andelyn Biosciences
Wuxi Advanced Therapies
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
Segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cell and Gene Therapy CDMO market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cell and Gene Therapy CDMO introduction, etc. Cell and Gene Therapy CDMO Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cell and Gene Therapy CDMO market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.